Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01100021 · ClinicalTrials.gov registry record · Phase 1
Hemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin
A Phase 1 study, sponsored by VIVUS.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT01100021 is a Phase 1 study that has completed, run by VIVUS. The registered enrollment target is 48 participants.
The verdict
NCT01100021, a Phase 1 study, has completed, sponsored by VIVUS.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to see if avanafil causes any changes in blood pressure and pulse rate when taken with doxazosin or tamsulosin.
Interventions
- DRUG Tamsulosin and avanafil
- DRUG Doxazosin and avanafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01100021
The ClinicalTrials.gov registry entry for NCT01100021 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VIVUS, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tamsulosin and avanafil is the first listed.
NCT01100021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01100021 about?
NCT01100021 is a clinical study titled "Hemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin". The purpose of this study is to see if avanafil causes any changes in blood pressure and pulse rate when taken with doxazosin or tamsulosin.
What is the current status of trial NCT01100021?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2010-02. Estimated completion is 2010-04.
What interventions are being tested in trial NCT01100021?
The interventions under investigation include: Tamsulosin and avanafil (DRUG), Doxazosin and avanafil (DRUG).
Who is sponsoring clinical trial NCT01100021?
This trial is sponsored by VIVUS, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.